Atlas chapter 16 · Cognition

Lion's Mane

Hericium erinaceus

E3±± — preliminary mixed-positiveR2 — human investigation extends across several controlled and pilot studies, but these do not constitute several tightly matched independent replications of one proposition. Populations, preparations, durations, cognitive domains and results differ. The field has repeated the topic; it has not yet tightly replicated the experiment.

Proposition / claim: Possible improvement in selected cognitive outcomes from defined Hericium erinaceus preparations in particular populations.
Evidence owner: Defined Hericium erinaceus preparations studied in specific human populations. The strongest controlled cognition signal belongs to the specific preparation, population, exposure period and cognitive outcomes actually studied. Evidence from fruiting-body material does not automatically transfer to mycelial preparations, erinacine-enriched extracts, whole powders, fermented-substrate products or arbitrary commercial Lion's Mane supplements, and vice versa.
Dominant uncertainty: Reproducibility of the cognition signal under standardized intervention conditions.

Organism: Lion's Mane
Tested intervention: Defined Hericium erinaceus preparations used in the controlled human cognition programme, including the oral fruiting-body preparation used in older adults with mild cognitive impairment.
Evidence target: Standardized preparation
Intervention description: The controlled human literature includes materially different Hericium erinaceus preparations, including fruiting-body material and other defined experimental preparations. Fruiting body, mycelium, extract, whole powder, fermented substrate and enriched preparations are not assumed chemically or clinically interchangeable. Evidence remains attached to the preparation, dose, population, duration and outcome actually tested.
Population: Selected human populations studied in the controlled cognition programme, including older Japanese adults with mild cognitive impairment in the strongest early placebo-controlled cognition signal.
Comparator: Placebo in the strongest randomized double-blind controlled cognition programme; comparator structures vary across the broader small human literature.
Outcome: Selected measured cognitive outcomes during defined supplementation periods. In the older mild-cognitive-impairment study, cognitive scores improved relative to placebo during treatment and declined again after treatment ended. The evidence does not establish permanent cognitive improvement, dementia prevention, Alzheimer's treatment or human neural regeneration.
Evidence maturity (E): E3±
Direction: ± — preliminary mixed-positive
Historical flag (H): Not specified at dossier level
Replication (R): R2 — human investigation extends across several controlled and pilot studies, but these do not constitute several tightly matched independent replications of one proposition. Populations, preparations, durations, cognitive domains and results differ. The field has repeated the topic; it has not yet tightly replicated the experiment.
Claim Gap (CG): CG0: "A small randomized placebo-controlled study found improved cognitive scores during Lion's Mane supplementation in older adults with mild cognitive impairment." CG1: "Preliminary controlled human evidence suggests certain Lion's Mane preparations may improve some cognitive outcomes, although results across the small literature are mixed." CG2: "Lion's Mane supports memory and cognition." CG3: "Lion's Mane boosts brain function and neuroplasticity." CG4: "Lion's Mane regenerates neurons and prevents dementia." Claim ceiling: CG1 for the strongest evidence-facing language; CG1-2 for carefully qualified general summaries. Each step beyond the ceiling adds a further population, outcome, duration, intervention or mechanistic transfer that the evidence does not carry.
Evidence Transfer Vector: Transferred proposition: "Lion's Mane supplements prevent cognitive decline." — I / P / O / D / R I — Intervention: specific studied preparations → generic supplement P — Population: small selected populations → general population O — Outcome: short-term cognitive score → prevention of cognitive decline D — Duration: months → years R — Replication: small mixed programme → established preventive effect
Taxonomic Transfer Confidence: HIGH relative to several more taxonomically problematic fungi. The canonical species identity is comparatively stable, but high taxonomic confidence does not imply equivalence between fruiting-body, mycelial, extract, powder or enriched preparations.
Intervention Transfer Confidence: LOW-MODERATE across materially different fruiting-body, mycelial and enriched-extract preparations. Evidence from one preparation does not automatically transfer to another, and neither hericenone nor erinacine content alone establishes clinical equivalence.
Safety: S1-2 — Lion's Mane appears generally well tolerated in the limited human trials available. Reported adverse effects across human studies include gastrointestinal discomfort, headache and allergic reactions. The human exposure database remains comparatively limited, and materially different extracts may create different exposure profiles.
Conservation: C0/C+ — Hericium erinaceus can be cultivated efficiently, so commercial production need not depend on wild harvesting. Cultivation may also support defined strains, controlled substrate, repeatable harvest conditions and chemical standardization.
Resolution zone: RZ-3
Next best experiment: First replicate the strongest existing human cognition proposition in an independent, preregistered, double-blind, placebo-controlled trial using one clearly defined population, such as older adults with objectively defined mild cognitive impairment, and one standardized preparation corresponding as closely as possible to the intervention underlying the strongest existing signal. Fully characterize species, fungal tissue, strain where available, substrate, chemistry, dose and manufacturing; prespecify one primary cognitive endpoint; use sufficient duration to assess clinical meaningfulness; and include post-treatment follow-up. Only if the cognition signal survives serious independent replication should head-to-head comparison of materially different preparations become the next efficient experiment.
Primary references: Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009 Mar;23(3):367-372. PMID: 18844328. DOI: 10.1002/ptr.2634. PMCID: none located (not PMC-indexed). — GRADE-OWNING / PRIMARY. Design: randomized, double-blind, parallel-group, placebo-controlled, with a 2-week run-in. Population: Japanese men and women aged 50-80 with diagnosed mild cognitive impairment. Sample size: 30 randomised (15 active / 15 placebo). Note: an n=31 figure circulating in secondary summaries could not be verified and is not adopted. Intervention: fruiting-body-derived material; four 250 mg tablets containing 96% Yamabushitake dry powder, three times daily (3 g/day). Preparation identity: fruiting-body dry powder, tablet form; strain, extraction and chemical standardisation NOT reported — PREPARATION IDENTITY PARTIALLY REPORTED. Comparator: matched placebo tablets. Duration: 16 weeks. Outcome: cognitive function scale based on the Revised Hasegawa Dementia Scale (HDS-R). Result: POSITIVE — significantly higher scores than placebo at weeks 8, 12 and 16. Post-treatment follow-up: 4 weeks after cessation; scores decreased significantly, i.e. the signal did not persist after intake stopped. Safety: laboratory testing showed no adverse effect. Owns the grade: YES — the single controlled human study that directly tests the grade-owning proposition in the stated population with the stated preparation class. Counts toward replication: it is the index study, not a replication. Major limitation: very small single-centre trial, one dementia-screening instrument used as the efficacy endpoint, short duration, benefit not durable after cessation. Transferability limitation: does not license transfer to mycelial or enriched extracts, to non-MCI populations, or to long-term prevention of cognitive decline.
Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomed Res (Tokyo). 2019;40(4):125-131. PMID: 31413233. DOI: 10.2220/biomedres.40.125. PMCID: none located. — CONTROLLED CORROBORATIVE (partial). Design: randomized, double-blind, placebo-controlled, parallel-group. Intervention: supplement containing Hericium erinaceus fruiting body. Preparation identity: fruiting body; dose and standardisation not verified from the abstract — PREPARATION IDENTITY INSUFFICIENTLY REPORTED at the level required for equivalence with Mori 2009. Duration: 12 weeks. Outcomes: Mini-Mental State Examination, Benton Visual Retention Test, Standard verbal Paired-Associate learning test. Result: MIXED — benefit reached significance on MMSE only; the two other instruments did not. Owns the grade: NO. Counts toward replication: PARTIALLY — same organism and fruiting-body class, but a different population, a different instrument set and only one of three endpoints positive; it does not constitute a tight replication of Mori 2009. Investigator independence: Shimizu and Ohnuki also appear on Nagano 2010, establishing a shared Japanese investigator lineage between those two publications. Major limitation: small, mixed endpoint results, incomplete preparation reporting. Transferability limitation: single-instrument significance does not support a general cognition claim.
Li IC, Chang HH, Lin CH, Chen WP, Lu TH, Lee LY, Chen YW, Chen YP, Chen CC, Lin DPC. Prevention of early Alzheimer disease by erinacine A-enriched Hericium erinaceus mycelia: pilot double-blind placebo-controlled study. Front Aging Neurosci. 2020 Jun 3;12:155. PMID: 32581767. PMCID: PMC7283924. DOI: 10.3389/fnagi.2020.00155. Registration: ClinicalTrials.gov NCT04065061. — CONTROLLED CORROBORATIVE; also PREPARATION IDENTITY. Design: 3-week screening followed by a 49-week double-blind, placebo-controlled, two-parallel-group randomized trial. Population: patients with diagnosed mild Alzheimer disease — NOT the MCI population of the grade-owning study. Intervention: erinacine-A-enriched cultured MYCELIUM capsules, 350 mg per capsule containing 5 mg/g erinacine A, three capsules daily. Preparation identity: mycelial, chemically standardised to erinacine A — materially different from the fruiting-body powder of Mori 2009. Comparator: placebo. Duration: 49 weeks. Outcomes: Cognitive Abilities Screening Instrument, MMSE, instrumental activities of daily living, biomarkers, diffusion tensor imaging, ophthalmic contrast sensitivity. Result: POSITIVE — active group maintained or improved MMSE and IADL while the placebo group declined on CASI. Owns the grade: NO — different preparation class and different diagnostic population. Counts toward replication: NO — a distinct proposition, not a replication of the MCI fruiting-body result. Major limitation: pilot size, industry co-authorship (Grape King Bio Ltd., a manufacturer of erinacine-A mycelium), funding statement not verified here. Transferability limitation: erinacine-enriched mycelium results must not be transferred to fruiting-body powders or to arbitrary commercial supplements.
Docherty S, Doughty FL, Smith EF. The acute and chronic effects of Lion Mane mushroom supplementation on cognitive function, stress and mood in young adults: a double-blind, parallel groups, pilot study. Nutrients. 2023 Nov 20;15(22):4842. PMID: 38004235. PMCID: PMC10675414. DOI: 10.3390/nu15224842. — CONTROLLED NULL / CONTRADICTORY; also PILOT / EXPLORATORY HUMAN. Design: randomized, double-blind, placebo-controlled, parallel-groups pilot. Population: 41 healthy adults aged 18-45 — a population in which no cognitive decline is expected. Intervention: 1.8 g Hericium erinaceus, single acute dose plus 28 days of chronic supplementation. Preparation identity: commercial preparation; tissue source and standardisation not verified — PREPARATION IDENTITY INSUFFICIENTLY REPORTED. Comparator: placebo. Duration: acute (60 min) and 28 days. Outcomes: cognitive battery including the Stroop task, plus subjective stress and mood measures. Result: MIXED, predominantly NULL — one acute finding (faster Stroop performance at 60 minutes, p=0.005); chronic supplementation produced only a non-significant trend toward reduced subjective stress (p=0.051), with null and some limited negative findings elsewhere. Owns the grade: NO. Counts toward replication: NO — different population, different endpoints, different exposure. Role in the dossier: the principal published controlled human evidence constraining Direction to plus-minus rather than plus. Major limitation: pilot sample size, healthy young population, multiple endpoints. Transferability limitation: null results in healthy young adults neither refute nor confirm the MCI finding.
Vigna L, Morelli F, Agnelli GM, Napolitano F, Ratto D, Occhinegro A, Di Iorio C, Savino E, Girometta C, Brandalise F, Rossi P. Hericium erinaceus improves mood and sleep disorders in patients affected by overweight or obesity: could circulating pro-BDNF and BDNF be potential biomarkers? Evid Based Complement Alternat Med. 2019 Apr 18;2019:7861297. PMID: 31118969. PMCID: PMC6500611. DOI: 10.1155/2019/7861297. — PILOT / EXPLORATORY HUMAN; NOT DIRECTLY COMPARABLE for cognition. Population: 77 overweight or obese volunteers, Milan, Italy. Duration: 8 weeks. Outcomes: self-reported depression, anxiety, sleep quality and binge eating, plus serum pro-BDNF and BDNF — mood, sleep and biomarker endpoints, NOT cognitive test performance. Result: reported improvement in depression, anxiety and sleep; pro-BDNF increased, BDNF unchanged. Design caveat: randomisation, blinding and placebo control could not be confirmed from the abstract record — DESIGN INSUFFICIENTLY VERIFIED. Owns the grade: NO. Counts toward replication: NO. Role in the dossier: frequently cited inside cognition reviews although it does not test a cognitive endpoint; recorded here specifically to prevent it being counted as cognition replication. Transferability limitation: BDNF movement is a biomarker, not a cognitive outcome.
Nagano M, Shimizu K, Kondo R, Hayashi C, Sato D, Kitagawa K, Ohnuki K. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res (Tokyo). 2010;31(4):231-237. PMID: 20834180. DOI: 10.2220/biomedres.31.231. PMCID: none located. — PILOT / EXPLORATORY HUMAN; NOT DIRECTLY COMPARABLE for cognition. Design: randomized, placebo-controlled comparison using Hericium erinaceus cookies versus placebo cookies. Population: 30 menopausal women. Duration: 4 weeks. Outcomes: Kupperman Menopausal Index, Center for Epidemiologic Studies Depression Scale, Pittsburgh Sleep Quality Index, Indefinite Complaints Index — mood and menopausal symptom endpoints, NOT cognitive testing. Result: reduction in CES-D and ICI scores. Owns the grade: NO. Counts toward replication: NO. Role in the dossier: shares investigators (Shimizu, Ohnuki) with Saitsu 2019 and is therefore relevant to the independence audit rather than to the cognition evidence base.
Kawagishi H, Ando M, Sakamoto H, Yoshida S, Ojima F, Ishiguro Y, Ukai N, Furukawa S. Hericenones C, D and E, stimulators of nerve growth factor (NGF)-synthesis, from the mushroom Hericium erinaceum. Tetrahedron Lett. 1991;32(35):4561-4564. DOI: 10.1016/0040-4039(91)80039-9. (See also Kawagishi H et al. Chromans, hericenones F, G and H from the mushroom Hericium erinaceum. Phytochemistry. 1992;32(1):175-178. DOI: 10.1016/0031-9422(92)80127-Z.) — PREPARATION IDENTITY; MECHANISTIC / PRECLINICAL. Establishes hericenones as NGF-synthesis-stimulating compounds isolated from the FRUITING BODY. Owns the grade: NO. Counts toward replication: NO. Role: supports the preparation distinction only. Limitation: in vitro NGF-synthesis stimulation is not a human cognitive outcome and does not transfer to memory, neuroplasticity, neural regeneration or dementia prevention.
Kawagishi H, Shimada A, Shirai R, Okamoto K, Ojima F, Sakamoto H, Ishiguro Y, Furukawa S. Erinacines A, B and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of Hericium erinaceum. Tetrahedron Lett. 1994;35(10):1569-1572. DOI: 10.1016/s0040-4039(00)76760-8. (See also erinacine D, Heterocycl Commun. 1996;2(1):51, DOI: 10.1515/hc.1996.2.1.51; erinacines E, F and G, Tetrahedron Lett. 1996;37(41):7399-7402, DOI: 10.1016/0040-4039(96)01687-5.) — PREPARATION IDENTITY; MECHANISTIC / PRECLINICAL. Establishes erinacines as cyathane diterpenoid NGF-synthesis stimulators isolated from cultured MYCELIUM, chemically distinct from the fruiting-body hericenones. Owns the grade: NO. Counts toward replication: NO. Role: the primary chemical basis for refusing to treat fruiting-body and mycelial preparations as interchangeable, and for refusing to equate hericenones with erinacines. Limitation: mechanistic only.
Menon A, Jalal A, Arshad Z, Nawaz FA, et al. Benefits, side effects, and uses of Hericium erinaceus as a supplement: a systematic review. Front Nutr. 2025;12:1641246. PMCID: PMC12434001. DOI: 10.3389/fnut.2025.1641246. — SYSTEMATIC REVIEW / SECONDARY SYNTHESIS; also SAFETY. Role: qualitative synthesis of human supplementation evidence including reported adverse effects; used for study identification, heterogeneity assessment and the safety narrative. Owns the grade: NO. Counts toward replication: NO — a synthesis cannot replicate a primary trial, and trials appearing in several reviews are not counted more than once. Limitation: narrative-qualitative synthesis; no pooled effect estimate for cognition.
Cornford N, Liu S, Charnley M. Hericium erinaceus: a possible future therapeutic treatment for the prevention and delayed progression of Alzheimer disease? A systematic review. Proc Nutr Soc. 2024. DOI: 10.1017/s0029665124005111. — SYSTEMATIC REVIEW / SECONDARY SYNTHESIS. Role: independent confirmation that the human cognition literature comprises a small number of small, heterogeneous trials rather than a replicated programme. Owns the grade: NO. Counts toward replication: NO. Limitation: conference-proceedings systematic review; no quantitative pooling. Audit note: no quantitative meta-analysis restricted to human Hericium erinaceus cognition randomized trials with pooled effect estimates was located during this pass — recorded as an evidence-base gap, not as a null result.
Herry J, Beaumont P. Anaphylaxie au champignon criniere de lion (Hericium erinaceus). Rev Fr Allergol. 2024. DOI: 10.1016/j.reval.2024.103825. (See also Maes M, Rademaeker M, Dooms-Goossens A. Occupational allergic contact dermatitis from the mushroom White Pom Pom, Hericium erinaceum. Contact Dermatitis. 1999;40(5):289-290. PMID: 10344494. DOI: 10.1111/j.1600-0536.1999.tb06073.x.) — SAFETY. Role: case-level allergic signals, one anaphylaxis following ingestion and one occupational contact dermatitis. Owns the grade: NO. Counts toward replication: NO. Interpretation limit: case reports establish that rare allergic reactions occur; they do NOT establish population incidence and must not be read as a causally quantified risk. Trial-level adverse events remain limited: Mori 2009 reported no adverse laboratory findings, and Li 2020 recorded four withdrawals for abdominal discomfort, nausea and skin rash. The human exposure database remains comparatively small, consistent with S1-2.
Kalucka IL, Olariaga Ibarguren I. Hericium erinaceus. The IUCN Red List of Threatened Species 2019: e.T70401627A70401637. DOI: 10.2305/IUCN.UK.2019-3.RLTS.T70401627A70401637.en. (See also Thongklang N et al. Commercial scale production of Yamabushitake mushroom, Hericium erinaceus, using rubber and bamboo sawdust substrates in tropical regions. Sci Rep. 2023;13:13316. DOI: 10.1038/s41598-023-40601-y; and Gonkhom D, Luangharn T, Raghoonundon B, Hyde KD, Stadler M, Thongklang N. Hericium: a review of the cultivation, health-enhancing applications, economic importance, industrial and pharmaceutical applications. Fungal Biotec. 2021;1(2):118-137.) — CONSERVATION. Role: the IUCN global assessment records Hericium erinaceus as Least Concern, and peer-reviewed cultivation literature confirms established commercial-scale sawdust cultivation, so supply need not depend on wild harvesting. Owns the grade: NO. Counts toward replication: NO. Interpretation limit: cultivability supports the conservation position only; it implies nothing about therapeutic equivalence between cultivated preparations. Audit note: a third-party website asserting Critically Endangered status contradicts the primary IUCN record and was rejected as unreliable.
Source chapter: Chapter 16, The Fungal Evidence Atlas